BridgeBio's unique structure creates dedicated subsidiaries for each program. This empowers small, focused teams closest to the science to make key decisions—"play calling on the field"—without layers of bureaucracy. This model dramatically accelerates development, leading to unprecedented output of new drugs.
Related Insights
To maintain a competitive edge, BridgeBio only pursues programs that are either "first in class" (a novel treatment where none exists) or "best in class" (a demonstrably superior option, like an oral pill versus a daily injection). This strict strategic filter is the core of their entire R&D pipeline selection process.
PostHog manages its 16+ product suite by assigning small, autonomous teams of roughly three engineers to each product. This "compound startup" approach allows them to go wide, competing with multiple point solutions while remaining flat and avoiding bureaucracy. The small team structure fosters ownership and rapid development.
The field of ophthalmology is particularly well-suited for a hub-and-spoke model because it utilizes a wide range of treatment modalities (small molecules, biologics, devices, gene therapy). This allows a central hub to leverage shared expertise in areas like ocular delivery and regulatory pathways across multiple, diverse spokes.
To avoid choosing between deep research and product development, ElevenLabs organizes teams into problem-focused "labs." Each lab, a mix of researchers, engineers, and operators, tackles a specific problem (e.g., voice or agents), sequencing deep research first before building a product layer on top. This structure allows for both foundational breakthroughs and market-facing execution.
By centralizing oversight at the hub, the model prevents teams from becoming emotionally attached to a single asset. This structure allows leadership to make objective, data-driven decisions to terminate unpromising programs without it being seen as a personal or career failure for the team involved.
To avoid bureaucratic bloat, organize the company into small, self-sufficient "pods" of no more than 10 people. Each pod owns a specific problem and includes all necessary roles. Performance is judged solely on the pod's impact, mimicking an early-stage startup's focus.
To avoid the pitfalls of scale in R&D, Eli Lilly operates small, focused labs of 300-400 people. These 'internal biotechs' have mission focus and autonomy, while leveraging the parent company's scale for clinical trials and distribution.
Former Biogen R&D head Al Sandrock defines the agility of a small company not just as speed, but as the ability to make decisions by informally gathering key people in the hallway, bypassing the need to schedule formal meetings. This contrasts with large organizations where many more people and committees are necessarily involved.
CZI's Biohub model fosters cross-disciplinary breakthroughs by physically sitting engineers and biologists together. This simple organizational tactic encourages informal communication and collaboration, proving more effective at solving complex problems than formal structures and reporting lines.
BridgeBio aims to become a "next generational" company like Regeneron. They believe the rare combination of two ingredients makes this possible: a successful, launched flagship product generating revenue, and a robust pipeline of multiple Phase 3 programs all set to read out within a year.